Clinical Trial Update: Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1

View source ↗

Summary

A clinical trial update notes cases of interstitial pneumonitis associated with combining EGFR tyrosine kinase inhibitors (EGFR-TKIs) and PD-1/PD-L1 inhibitors …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGFR-TKI (unspecified) (epidermal growth factor receptor tyrosine kinase inhibitor)
• PD-1/PD-L1 inhibitor (unspecified)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Status: COMPLETED